100 related articles for article (PubMed ID: 7935998)
1. Immune reactive proteins in renal cell carcinoma patients treated by IFN alpha alone or in combination with vinblastine.
Juranić Z; Stanojević-Bakić N; Maletić V; Borkovacki R
Neoplasma; 1994; 41(4):229-32. PubMed ID: 7935998
[TBL] [Abstract][Full Text] [Related]
2. Correlation of clinical and immunological parameters of metastatic renal cell carcinoma patients undergoing therapy with interleukin 2, interferon-alpha and retinoic acid.
Elsässer-Beile U; Kölble N; Grussenmeyer T; Wetterauer U; Schultze-Seemann W
Anticancer Res; 1998; 18(3B):1883-90. PubMed ID: 9677439
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant interleukin-2, interferon-alpha, and 5-fluorouracil immunochemotherapy after radical nephrectomy for locally advanced renal cell carcinoma.
Hong SK; Kwak C; Lee SE
Urology; 2005 Sep; 66(3):518-22. PubMed ID: 16140069
[TBL] [Abstract][Full Text] [Related]
4. Our experience with interferon alpha: renal cell carcinoma.
Merimsky O; Chaitchik S
Mol Biother; 1992 Sep; 4(3):130-4. PubMed ID: 1445666
[TBL] [Abstract][Full Text] [Related]
5. Multi-modal treatment of primarily using continuous subcutaneous interferon-alpha injection in combination with surgery and/or radiotherapy.
Maruoka M; Fujimura M; Kawamura K; Suzuki S; Hamano M; Nishikawa Y; Nagayama T
Int J Urol; 2005 May; 12(5):442-8. PubMed ID: 15948742
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-2, interferon-alpha, 5-fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinoma: a prospective phase II study: the experience of Rambam and Lin Medical Centers 1996-2000.
Gez E; Rubinov R; Gaitini D; Meretyk S; Best LA; Native O; Stein A; Erlich N; Beny A; Zidan J; Haim N; Kuten A
Cancer; 2002 Oct; 95(8):1644-9. PubMed ID: 12365011
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
8. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
[TBL] [Abstract][Full Text] [Related]
9. Dendritic cell therapy in combination with interferon-alpha for the treatment of metastatic renal cell carcinoma.
Tatsugami K; Eto M; Harano M; Hamaguchi M; Miyamoto T; Morisaki T; Furue M; Akashi K; Naito S
Int J Urol; 2008 Aug; 15(8):694-8. PubMed ID: 18564205
[TBL] [Abstract][Full Text] [Related]
10. Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience.
Franklin JR; Figlin R; Rauch J; Gitlitz B; Belldegrun A
Semin Urol Oncol; 1996 Nov; 14(4):230-6. PubMed ID: 8946623
[TBL] [Abstract][Full Text] [Related]
11. Does vinblastine add to the potency of alpha interferon in the treatment of renal cell carcinoma?
Merimsky O; Shnider BI; Chaitchik S
Mol Biother; 1991 Mar; 3(1):34-7. PubMed ID: 2069758
[TBL] [Abstract][Full Text] [Related]
12. Recombinant alpha-interferon plus vinblastine in metastatic renal-cell cancer: analysis of response and survival in 58 evaluable patients.
Bergerat JP; Ford J; Herbrecht R; Dufour P; Oberling F; Jacqmin D; Bollack C; Prevot G; Salze P; Jurascheck F
Prog Clin Biol Res; 1990; 348():137-50. PubMed ID: 2385604
[No Abstract] [Full Text] [Related]
13. Long-term outcome of postoperative interferon-alpha adjuvant therapy for non-metastatic renal cell carcinoma.
Gotoh A; Shirakawa T; Hinata N; Wada Y; Hara I; Fujisawa M; Kawabata G; Okada H; Arakawa S; Kamidono S
Int J Urol; 2004 May; 11(5):257-63. PubMed ID: 15147539
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of adjuvant interferon-alpha therapy following curative resection in renal cell carcinoma: before the molecular targeting therapy era.
Kai F; Takayama T; Sugiyama T; Furuse H; Mugiya S; Ozono S
Jpn J Clin Oncol; 2009 May; 39(5):310-4. PubMed ID: 19363055
[TBL] [Abstract][Full Text] [Related]
15. [Renal cell carcinoma-interferon therapy, its clinical adaptation and limitations].
Noguchi S; Hosaka M
Gan To Kagaku Ryoho; 1991 Nov; 18(14):2383-9. PubMed ID: 1952957
[TBL] [Abstract][Full Text] [Related]
16. Cytokine combinations: therapeutic use in patients with advanced renal cell carcinoma.
Bukowski RM
Semin Oncol; 2000 Apr; 27(2):204-12. PubMed ID: 10768599
[TBL] [Abstract][Full Text] [Related]
17. Can the CD4+/CD8+ ratio predict the outcome of interferon-alpha therapy for renal cell carcinoma?
Hernberg M; Muhonen T; Pyrhönen S
Ann Oncol; 1997 Jan; 8(1):71-7. PubMed ID: 9093710
[TBL] [Abstract][Full Text] [Related]
18. [Interferon-alpha therapy in hypernephroma].
Sagaster KP
Wien Med Wochenschr; 1993; 143(16-17):443-7. PubMed ID: 8273370
[TBL] [Abstract][Full Text] [Related]
19. Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens.
Miyake H; Sakai I; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M
Int J Urol; 2009 May; 16(5):465-71. PubMed ID: 19467119
[TBL] [Abstract][Full Text] [Related]
20. Interferon in metastatic renal cell carcinoma.
Fosså SD
Semin Oncol; 2000 Apr; 27(2):187-93. PubMed ID: 10768597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
